Retour
NKGen Biotech Inc (NKGN) Gagner
Graphique du cours de l'action NKGN
NKGN Gagner
NKGen Biotech Inc
$0.06
0%
$0
À la fermeture : Mar 25, 16:00:00 GMT-4
$0.06
0%
$0
Post-Marché: Mar 25, 20:00:00 GMT-4
Earnings FAQ
Comment le bénéfice par action récent de NKGN se compare-t-il aux attentes ?
Comment les revenus de NKGen Biotech Inc NKGN se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour NKGen Biotech Inc ?
Quel est le score de qualité des bénéfices pour NKGen Biotech Inc ?
Quand NKGen Biotech Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de NKGen Biotech Inc ?
NKGen Biotech Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.06
Prix d'ouverture
$0.06
Plage de la journée
$0.06 - $0.06
Plage de 52 semaines
$0.001 - $0.46
Volume
2.7K
Volume moyen
3.6K
Rendement en dividend
--
BPA (TTM)
-1.92
Capitalisation boursière
$7.8M
Qu’est-ce que NKGN ?
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 26 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.